RESEARCH DOSSIER
EU Product Liability Directive 2024/2853 and Insurance Implications
Abstract. Directive (EU) 2024/2853 establishes the European Union's revised harmonized rules for liability for damage caused by defective products. Its treatment of software, digital manufacturing files, related digital services, post-market manufacturer control, substantially modified products, evidentiary disclosure, statutory presumptions, and accountable economic operators changes the legal environment in which product-liability risk is generated, contested, financed, and insured. This monograph examines the enacted Directive together with its May 7, 2026 corrigendum, the transitional continuation of Directive 85/374/EEC, official EU explanatory materials, relevant judicial decisions, scholarly interpretation, and insurance valuation standards. The analysis differentiates four objects that are often conflated: a natural person's right to statutory compensation; the potential defendant's liability under applicable national implementation; the insurer's separate and contract-specific coverage obligation; and the insurer's financial measurement of uncertain future cash flows. It identifies the new Directive's prospective boundary as products placed on the market or put into service after December 8, 2026, while Member States must transpose its rules by December 9, 2026. This distinction, corrected in May 2026, is central to exposure identification and coexistence of old and new product-liability cohorts. The study develops an evidence-based insurance interpretation of the legal changes without proposing a new doctrine or asserting observed claims effects that cannot yet be measured. The principal conclusions concern extended digital-product exposure, more intricate allocation among manufacturers and supply-chain actors, conditional changes in litigation information and proof, new categories of compensable personal and nonprofessional data injury, and operational requirements for underwriting, incident preservation, claims triage, reserving, reinsurance, and contract-year mapping. At the research cutoff, the Directive's future application remains prospective; its eventual effects on claim frequency, defense cost, premiums, and insurance availability are hypotheses requiring subsequent data.
Keywords: Directive (EU) 2024/2853; European product liability; liability insurance; products-completed operations; defective software; artificial intelligence; cybersecurity; causation; disclosure of evidence; presumptions; supply-chain liability; occurrence-based coverage; claims-made coverage; loss reserving; reinsurance; Solvency II; IFRS 17; legal transition.
Introduction
A liability directive allocates obligations between injured persons and economic operators. A liability insurance contract allocates a specified subset of those obligations and related costs between an insured and an insurer. The relationship is consequential because a legal enlargement of potential liability can change insured exposure, yet its translation into insurance payments depends on policy language, insured identity, attachment, jurisdiction, exclusions, limits, aggregation, retentions, and the insurer's claims decisions. The relationship also operates in reverse: contractual exclusions do not diminish a claimant's statutory right against the responsible economic operator. Article 15 of the revised Directive protects that distinction by prohibiting contractual reduction or exclusion of the economic operator's liability in relation to an injured person.
The enacted 2024 product-liability directive, read together with the May 2026 corrigendum, is the controlling starting point. The prior 1985 product-liability directive remains relevant because products from older market-placement cohorts continue to be governed by it under the transitional rule. The European Commission's official product-liability explanation describes the modernization in terms of digital technology, global supply chains, and consumer compensation. De Luca's European Parliament briefing reconstructs the legislative development and major objectives. Secondary interpretation offers useful questions, but the enacted text and subsequent correction control precise dates and legal tests.
The research question is therefore how an enacted change in product-liability conditions influences the distribution, timing, evidence, and measurement of losses to which insurance contracts may respond. The unit of legal analysis is a cause of action under the Directive as implemented in a particular Member State, attached to a specified product and injured person. The unit of insurance analysis is an insured risk and policy responding, or potentially responding, to that cause of action. Neither unit is equivalent to a reported insurance claim: a legal claim may remain uninsured, a notification may never result in payment, and several policies may be implicated by one physical failure.
This monograph uses doctrinal comparison, source verification, insurance-contract analysis, and explicit hypothetical actuarial reasoning. It does not report a post-December-2026 claim sample because the prospective product-cohort boundary has not yet arrived at the November 16, 2026 research cutoff. Consequently, proposed premium, severity, and reserving effects are conditional mechanisms rather than measurements of realized reform. Where the law leaves implementation or contractual consequences to national law or particular forms, the discussion identifies that variable instead of treating it as a harmonized result.
The cross-disciplinary location is established by the published Science areas Casualty and Liability Insurance, Insurance Regulation, Insurance Contract Law, and Commercial Insurance. Those internal navigational links identify disciplinary relationships; the external links in the scientific argument identify source evidence. The analysis concentrates on the Directive's product-liability pathway and on the insurance consequences that follow from that pathway.
Definitions, History, Legal Sources, and Subject Boundaries
The legal architecture from 1985 to 2024
Council Directive 85/374/EEC created a harmonized, fault-independent product-liability regime. Its basic architecture required proof of damage, defect, and causal connection, while leaving important matters of remedies and litigation procedure to national law. Article 9 limited covered property damage through a 500 ECU threshold and requirements linked to ordinary private use. Articles 10 and 11 distinguished a knowledge-based three-year limitation period from a ten-year extinguishment period. These elements can be checked against the original directive's operative provisions. The 1985 design principally addressed manufactured tangible goods in comparatively stable supply chains.
The revised 2024 instrument was adopted October 23, 2024 and published November 18, 2024. Its subject is damage suffered by natural persons and caused by defective products, with common rules for economic-operator liability. Article 3 articulates the harmonization constraint, subject to the Directive's stated exceptions. It is therefore important to distinguish harmonized liability elements from the considerable remaining national-law variation in procedure, quantification of loss, additional causes of action, and contractual insurance regulation.
The temporal rule is unusually important. Article 2(1), as expressly corrected by the Official Journal corrigendum of May 7, 2026, applies to products placed on the market or put into service after December 8, 2026. The earlier wording in the initial act referred to after December 9 and was corrected. Article 21 repeals Directive 85/374/EEC with effect from December 9, 2026 but preserves its applicability to products placed on the market or put into service before that date. Article 22 requires national transposition by December 9, 2026. In ordinary chronological terms, the intended new product cohort begins December 9, 2026. Product placement, rather than injury occurrence, is the central statutory cohort identifier. Injury and insurance-policy dates remain distinct.
An EU directive addresses Member States and requires national implementation. As of the research cutoff, a complete country-by-country determination of adopted, commenced, and judicially interpreted national implementing measures has not been established in this study. The national text, its entry into force, and the particular claim's forum must be checked before applying the discussion to a real dispute. The directive also has EEA relevance, but EEA application requires a separate legal-status check. The study therefore does not assume automatic equivalence across the EU, EEA, the United Kingdom, Switzerland, or other jurisdictions.
Products, related services, and control
Article 4(1) defines products to include movables whether integrated into other movable or immovable objects, electricity, raw materials, software, and digital manufacturing files. A digital manufacturing file carries functional information for automated production of a tangible item. A related service is a digital service integrated into or interconnected with a product whose absence would prevent one or more product functions. The distinction protects the legal role of software and safety-critical connected functionality without converting every digital interaction or stand-alone informational service into an insured product claim.
The Commission's explanation of software and AI confirms that software, including AI systems, is considered within the new product concept. The Directive's recital 13 distinguishes executable software from information, media-file content, and mere source code. The statutory exception for free and open-source software developed or supplied outside a commercial activity appears in Article 2(2); it should not be transformed into a universal exemption for all open-source components or all commercial users of such software. A manufacturer incorporating open-source components into a marketed product may remain liable for the resulting defective marketed product.
Article 4 also defines manufacturer control in terms of developing, authorizing, consenting to, integrating, and updating products or components. This concept matters because a product's risk state may evolve after initial placement. The insurance analyst should record the software version, update provenance, remote-service relationships, and dates of authorization or control, alongside the initial product cohort. Such recordkeeping is a rational inference from the legal criteria; it is not a separately imposed recordkeeping obligation created by this monograph.
A substantially modified product may enter a new liability position, and Article 8(2) treats the person making a substantial modification outside the original manufacturer's control as a manufacturer where the relevant conditions are satisfied. Its materiality definition is connected to product-safety rules or, absent a specified threshold, to changes in function, foreseeable risk, and hazard. Repair, recycling, aftermarket intervention, remanufacturing, and connected-device modification therefore require facts rather than category-wide labels.
Boundaries of the research object
This study addresses the Directive's civil product-liability regime and its implications for commercial liability insurance. Other routes can coexist. A contract or negligence action may have a different standing rule, burden, recoverable damage, or defendant; the Directive preserves specified independent rights under Article 2(4). Regulatory fines, warranty remedies, replacement of the defective product itself, professional-only property damage, pure economic loss without qualifying injury, and privacy infringement alone are outside the particular compensation categories stated in Article 6, although another legal regime or an insurance coverage may address them. The distinction between statutory scope and insurance-product labeling prevents the false proposition that every technologically caused loss is a loss under the Product Liability Directive.
The judgment in Boston Scientific (2015) illustrates how the Court of Justice applied the previous directive to the potential defect of high-risk implanted medical devices and necessary replacement surgery. The judgment in W and Others (2017) shows the importance of judicial treatment of serious, specific, and consistent evidence where scientific consensus is absent, without simply eliminating the claimant's burden. These are precedents under the former framework. Their relevance to questions of defect, causation, and proof should be analyzed in light of the revised statutory text rather than mechanically transplanted as if they construed the new Directive.
The first methodological conclusion follows: product identity, market-placement cohort, applicable national law, allegedly defective component, injured natural person, and damage category must be established before any coverage assessment. Omitting one of these variables can make an apparently coherent insurance-loss narrative legally untestable.
Defective Product Categories, Damage, and Burden of Proof
Defectiveness is a legal safety assessment
Article 7(1) treats a product as defective when it fails to provide the safety a person is entitled to expect or that Union or national law requires. Article 7(2) requires assessment of all circumstances, including presentation, design, instructions, reasonably foreseeable use or misuse, interactions with other products, lifecycle control, relevant product-safety and cybersecurity requirements, product recalls, vulnerable user groups, and products designed to prevent damage. Article 7(3) makes clear that the mere existence of a better subsequent product does not of itself prove defectiveness. These criteria are in the enacted defectiveness provisions.
From an underwriting perspective, defectiveness extends across multiple technically distinct failure mechanisms: a design that is unsafe under foreseeable use; deficient manufacturing or component integration; misleading instructions or warnings; a safety-relevant software update; a failure to supply a necessary security update while under manufacturer control; or a connected service that impairs a product function. These are practical investigative classifications, not a claim that the Directive itself creates separate statutory causes of action called design defect, manufacturing defect, and warning defect. Insurers need the classification because evidence sources and correlated portfolios differ. A manufacturing-batch failure may connect policyholders to a common component supplier; a centrally distributed update may affect many product versions and policy years; defective instructions may create broad and sustained exposure.
The legal test cannot be reduced to a compliance checklist. Proof of compliance is evidence that may matter to the court; it is not an automatic safe harbor against a product's being found defective. Conversely, under Article 10(2)(b), an established breach of mandatory safety requirements intended to protect against the particular damage may trigger a rebuttable presumption of defectiveness. The precise protective purpose of the breached requirement is thus critical. A company cannot infer that every regulatory noncompliance, however unrelated to an injury, establishes defectiveness for that injury.
Compensable heads of damage
Article 6 covers death or personal injury, expressly including medically recognized damage to psychological health. It also covers qualifying damage to or destruction of property other than the defective product, excluding property used exclusively for professional purposes and the specified integrated-product/component situation. A third category comprises destruction or corruption of data not used for professional purposes. Material loss resulting from these categories is compensable; nonmaterial loss arising from such damage is compensable insofar as national law permits. The Directive's damage definition should be read literally before drawing conclusions about insurance.
This is an important scope expansion relative to the former 500 ECU property threshold and private-use tests. Removing a minimum property-damage threshold can make some small events legally eligible, though the cost of pursuit, national procedure, evidence, defense arrangements, deductibles, and policy terms still affect notification and payment. It does not prove that small-claim frequency will rise by any particular amount. Claim cost may increase because low-severity incidents become actionable, or practical transaction costs may suppress many potential claims. Both mechanisms must remain in a prospective assessment.
A medically recognized psychological injury should be distinguished from an unverified subjective reaction and from privacy distress unconnected to qualifying injury. A destroyed household photo archive can present a nonprofessional data-loss question under Article 6; ordinary professional data loss falls outside that particular head, even when a cyber or technology errors-and-omissions policy offers a separate path. Similarly, the defective product itself is excluded from compensation under the Directive. Insurance policies vary as to products exclusions, recall costs, sistership exclusions, impaired-property provisions, loss-of-use language, cyber exclusions, and consequential losses. Statutory damages and covered damages are not interchangeable sets.
Disclosure and conditional presumptions
Article 9 permits a claimant who presents facts and evidence sufficient to support the plausibility of a claim to request relevant evidence at the defendant's disposal. The defendant may also seek relevant evidence where its need to counter the claim is sufficiently substantiated, under national-law conditions. Disclosure is confined to what is necessary and proportionate. Courts must account for confidentiality, trade secrets, third-party interests, and accessible presentation when justified. The disclosure provisions in Article 9 establish a structured court-supervised exchange, not general unrestricted access to a manufacturer's proprietary code or all records.
Article 10(1) preserves the claimant's obligation to prove defect, damage, and causal link. Article 10(2) creates presumptions of defectiveness in specified circumstances: failure to comply with an Article 9(1) disclosure order, proof of breach of relevant mandatory safety requirements, or an obvious malfunction during reasonably foreseeable use or in ordinary circumstances. Article 10(3) supplies a presumption of causal link where defectiveness has been established and the damage is typically consistent with the defect. Article 10(4) permits a presumption of defectiveness, causation, or both where technical or scientific complexity creates excessive difficulties and the claimant demonstrates likelihood despite evidence disclosure. Article 10(5) expressly allows defendants to rebut these presumptions. The operative burden-of-proof provisions require each condition to be individually examined.
Goicovici (2025), in a study of disclosure, damage taxonomies, and defectiveness, identifies the interdependence between access to evidence, classification of injury, and available defenses. That doctrinal emphasis reinforces a claims-handling point: evidence is itself an exposure-control variable. A preserved update log, incident chronology, product-safety report, or expert analysis may change the ability to establish or rebut a statutory presumption. Disclosure failures may produce a substantive litigation consequence even where the technical system was not ultimately defective.
The insurer should evaluate each element separately: plausibility of pleaded claim; evidence held by the defendant; proportional scope of disclosure; existence of a safety rule with the correct protective purpose; facts of malfunction; established or presumed defectiveness; injury type; causal consistency; scientific complexity; and rebuttal evidence. An allegation that AI systems are complex is insufficient by itself to establish the specific conditions in Article 10(4). The litigation effect depends on judicial application and national procedural rules.
Defenses and apportionment
Article 11 retains specified defenses, including development-risk issues linked to the objective state of accessible scientific and technical knowledge, while restricting the post-market-defect defense when the defect arises from software, related services, missing necessary safety updates, or substantial modification within the manufacturer's control. Article 18 preserves or permits specified national derogations from the development-risk defense under notification conditions. Defense availability is therefore contingent on the precise defendant, component, control period, national measure, and relevant provision.
Article 12 provides joint and several liability where multiple economic operators are liable for the same damage under the Directive, without displacing national contribution and recourse rules. Article 13 distinguishes third-party conduct from contributory fault of the injured person. Article 14 addresses recourse among operators. Article 12(2) also contains a narrow contractual-waiver exception protecting qualifying micro and small software-component enterprises from an integrating manufacturer's recourse if the statutory conditions are met. These distinctions mean that the initial claimant-facing payment allocation and the eventual net share borne by an insured or insurer can diverge.
For actuarial analysis, a case's final liability share should not be assumed to equal its initial defense allocation or its maximum joint-and-several exposure. Every stage has its own probability, cost, and timing. A reserve that ignores the possibility and timing of contribution recoveries overstates some expected ultimate net losses; a reserve that credits speculative recoveries as certain understates them. The appropriate treatment depends on the insurer's accounting and prudential framework, policy contract, counterparty quality, and collection evidence.
Digital Products, Supply Chains, and Claimant Rights
Software as product and evolving safety condition
The explicit inclusion of software and AI systems in the product concept is a material legal change. Stand-alone commercially supplied software, embedded software, and software delivered by network or cloud-based means may be relevant, subject to the product definitions and exceptions. A connected digital service can be a component when the statutory functional relationship is met. The consequence is that the claimant may locate a safety-relevant defect in code, updates, firmware, or integrated functionality rather than in a tangible casing or physical component. The Commission's software-and-AI guidance and the Directive's recitals address the logic of that expansion.
For the insurer, a digital-product claim requires a time-indexed technical description. The legally relevant questions include which release was initially placed on the market, what update was deployed, whether the manufacturer authorized that update, whether the related service remained within manufacturer control, what the reasonably foreseeable product interaction was, and whether a necessary safety update was omitted. The factual chain matters more than generic labels such as AI accident or cyber incident. One code defect can be implicated in many devices; one physical device can move through several software states; many claimants may experience different injury mechanisms despite shared code.
The Directive's liability focus is damage caused by defectiveness. A data breach, by itself, does not automatically yield an Article 6 claim. Loss of nonprofessional data, injury, or qualifying property damage may bring the conduct within the enumerated categories if defect and causation are established. Separate data-protection, contract, negligence, professional-liability, or regulatory frameworks can apply on their own terms. The insurer's products-liability, technology E&O, cyber, and general-liability wording may respond differently to the same factual event, especially where the trigger requires physical injury or property damage or defines electronic data as property.
Cybersecurity and product safety
Article 7 explicitly includes relevant safety-related cybersecurity requirements among the circumstances of defectiveness. The Cyber Resilience Act, Regulation (EU) 2024/2847, imposes a separate framework for products with digital elements with phased application: notably, Article 14 applies from September 11, 2026 and the general application date is December 11, 2027, with additional intermediate provisions. This temporal separation matters. A prospective PLD analysis should not infer that every requirement of another regime was already applicable to every product on December 9, 2026. The relevant requirement, covered product, and commencement date must be identified.
Safety-related cybersecurity evidence can include threat models, vulnerability discoveries, remediation decisions, release records, dependency inventories, penetration-testing outputs, deployment traces, and instructions given to customers. A known vulnerability may matter to defectiveness, but the threshold for liability remains the Directive's safety standard and causal connection. Failure to provide a necessary update within the manufacturer's control must be evaluated against technical facts and the actual statutory defense structure. That assessment is different from a presumption that every compromised product was defective from the outset.
The EU AI Act establishes its own framework of AI obligations and phased dates. The revised PLD references AI systems as products for liability purposes, but it does not thereby create a universal, stand-alone AI insurance mandate. Regulatory classification of an AI system, product-safety duties, and tort liability must be mapped as separate but potentially interacting legal dimensions. For a manufacturer and insurer, this supports integrated technical documentation rather than a single all-purpose conclusion that an AI Act breach conclusively proves a product-liability claim.
Responsible operators and transnational supply chains
Article 8 begins with the product manufacturer and certain component manufacturers where their components render a final product defective. In the case of a manufacturer established outside the Union, the Directive addresses EU-based importers, authorized representatives and, where the specified prior categories are absent, fulfillment service providers. It further regulates distributors, online-platform involvement, and substantial modification under defined circumstances. The statutory order of potential operators should be read carefully: an online marketplace is not liable merely because a defective product appeared in a search result, and an ordinary third-party logistics participant is not automatically the principal manufacturer. Its actual statutory role and conduct matter.
This distribution of potential defendants improves claimants' opportunities to find an accountable operator inside the Union. It also changes the insurer's risk identification. A European importer may face claimant-facing obligations for a product engineered abroad; a software-component supplier may be sued along with an integrator; an entity that materially modifies a device may become the legally relevant manufacturer of the modified product. International insurance programs can consequently encounter local admitted-policy questions, additional-insured provisions, vendor endorsements, choice-of-law conflicts, contractual indemnities, aggregation disputes, and contribution actions. These issues follow from the structure of the legal chain, but their insurance outcomes require the actual contract and jurisdiction.
Two complementary exposures should be separated. The first is gross claimant-facing liability, potentially joint and several under Article 12. The second is the net incidence after contractual indemnities, contribution rights, settlements, and reinsurance. A strong hold-harmless agreement may improve expected recovery between parties, yet it cannot by itself extinguish the injured person's statutory right under Article 15. Credit risk and enforcement cost become part of the net-exposure problem.
Claimant standing and the nature of injury
Article 5 centers injured natural persons and permits defined successors, subrogees, and representatives to bring claims. A right of subrogation may therefore create claims brought by a compensating entity, depending on Union and national law. The existence of social, health, travel, or property insurance does not establish automatic reimbursement: standing, applicable law, underlying payment, and recoverable heads of damage must be examined.
Article 6's data and psychological-health categories provide claimants with specific routes that were not expressed in the same way under the former product-liability regime. They also reveal boundaries: data must be nonprofessional under the clause, and medically recognized mental-health injury is not equivalent to ordinary inconvenience. A practical scenario is a defective consumer medical-monitoring device whose software sends an unsafe alert that causes medically documented injury. Another is defective home-storage firmware that irreversibly corrupts household data. In either case the plaintiff must establish the required legal elements or satisfy the statutory tests for presumptions. The insurer must then separately identify whether its policy covers that loss category.
The economic meaning of allocation
The increase in legally relevant actors can enlarge opportunities for a claimant to seek recovery and can increase defense coordination costs. It does not necessarily enlarge the total economic loss caused by an incident. Multiple defendants may defend one injury; their insured policies may duplicate defense expenditure or allocate it; recourse actions may redistribute rather than create underlying damages. A credible insurance analysis distinguishes unique injured persons, unique events, filed proceedings, named defendants, policies notified, claims booked, defense expenses, compensation paid, and ultimate net insured loss. Counts from these levels cannot be substituted for one another.
Rimkutė (2026), in the regulatory function of the new Directive, argues that the instrument's design also serves market and regulatory objectives in addition to individual redress. The insurance inference is that product design and compliance incentives may change alongside legal-claim incentives. Improved safety could reduce physical events even if claim eligibility and reporting increase. This competing mechanism is indispensable to any defensible prediction of long-run insured loss.
Transposition Timing, Insurance Contracts, and Insurer Response
Legal time and policy time are different clocks
The revised Directive has a defined prospective product cohort and a separate implementation deadline. Article 2, as corrected, points to market placement or putting into service after December 8, 2026; Article 22 points to national transposition by December 9, 2026. Article 21 preserves the previous regime for earlier products. The corrected Article 2 date is therefore a controlling classification fact, not a typographic footnote. A loss occurring in 2032 may still involve a product first placed on the market in 2025 and belong to the earlier statutory cohort. Conversely, a December 2026 product may generate injury years later under the revised framework.
For insurance, at least seven clocks may be relevant: product market placement; manufacturer-control period and update deployment; occurrence or injury manifestation; first claim against the insured; first notice to the insurer; defense and settlement payments; and accounting valuation date. A products-completed-operations form may use occurrence-based attachment. A technology or professional form may instead be claims-made, sometimes with reporting conditions, a retroactive date, and extended reporting provisions. These are contractual mechanisms whose specific wording and national interpretive law govern. The Directive's effective-date rule does not replace them.
A simple temporal example illustrates the distinction. A connected device is placed on the EU market in January 2027, receives an authorized update in 2029, injures a user in 2030, and yields a formal claim in 2031. The revised PLD cohort follows the 2027 placement; the product defect and control analysis may require the 2029 update; an occurrence policy may look to 2030 injury; a claims-made policy may look to the 2031 claim and notification requirements. Each year is a different possible legal or insurance anchor. Reinsurance attachment and aggregation must then be separately examined.
Article 16 supplies a three-year limitation period measured from the injured person's actual or reasonably required knowledge of damage, defectiveness, and identity of the relevant economic operator, subject to national suspension and interruption rules. Article 17 provides a ten-year expiry period from market placement or putting into service (or, for substantial modification, the relevant subsequent placement), with a 25-year exception for personal injury whose latency prevented earlier proceedings. The limitation and expiry rules are statutory claim boundaries; they should not be casually equated with the term of an insurance contract, notification deadline, or insurer's reserve horizon.
The coverage question
An insurer's first coverage analysis asks who is insured and in what capacity. A manufacturer may have commercial general-liability products coverage; a supplier may hold separate component coverage; an importer may hold vendor or product-liability coverage; a software developer may rely on technology E&O, cyber, professional indemnity, or a combined wording. None of those labels establishes coverage. The operative questions include insured status, insuring agreement, qualifying injury or damage, relevant territorial and jurisdiction clauses, policy trigger, limit and sublimit, insured-retained layer, exclusions, endorsements, conditions, defense and settlement provisions, and other-insurance clauses.
A statutory claim for destruction of household data may fall between policy forms that treat data as excluded electronic property and forms that expressly cover a defined digital-loss event. A claim for psychological injury may meet the Directive's damage definition while triggering a dispute over whether the insurance form's bodily-injury definition includes the particular medically recognized condition. A software defect may involve a product bodily-injury event, a pure financial loss, or both; coverage analysis must allocate facts and claim heads accordingly. This is an inference from the collision of statutory and contractual definitions, not an assertion of uniform industry wording.
Defense costs are distinct from indemnity. Some wordings impose a duty to defend, some reimburse specified defense expenses, and some grant defense control or consent rights. Costs may erode limits or sit outside them. Where several supply-chain parties are sued, insurer-appointed counsel may face related-party conflicts and coordination challenges. Court-supervised disclosure and expert-intensive proof may increase the amount or duration of defense work; compliance-oriented digital records may also shorten disputes. Both outcomes are plausible.
Product recall and corrective action expenses form another distinct category. The economic operator might need to patch, remove, replace, or warn even before any qualifying person suffers loss. The Directive's claimant-compensation architecture does not automatically cover those first-party preventive expenses. Dedicated recall or crisis-management insurance, if purchased, uses its own triggers and exclusions. A contract's cost to repair the defective product itself is also analytically distinct from third-party compensation under Article 6.
Claims management and evidence governance
The Directive increases the value of structured first-notice-of-loss information. A report should identify the product and batch, software build, initial market-placement date, affected jurisdictions, alleged injury, claimed heads of damage, warnings, safety standards, relevant updates, and involved suppliers. It should also record the claimant's asserted factual theory, potential Article 10 presumptions, and material needed to rebut them. Where an incident may affect many devices, a common technical investigation can support consistency while individual records remain necessary for injury and causation.
Article 9 requires proportionate court-controlled disclosure and attention to trade secrets. Effective claims practice therefore connects legal counsel, product-safety professionals, security engineers, records management, and insurers. Preservation of an audit trail should respect applicable privacy, confidentiality, cybersecurity, and evidence law; it is not authorization to collect unlimited personal data. The product-liability information environment can be complex, but disciplined recordkeeping lowers avoidable uncertainty.
The insurer should distinguish notification, exposure opening, reserve setting, payment authorization, settlement, contribution pursuit, and closure. A mass notification caused by one software update is not evidence of the same number of compensable injuries. An exposure file may be opened without litigation; a court may establish defectiveness without an insurer owing indemnity; a reserved claim may develop into zero payment. Consistent classifications are necessary for any future empirical assessment of this reform.
Underwriting and price formation
Expected loss can be expressed in standard actuarial terms as claim frequency times expected ultimate severity, adjusted for coverage, expenses, timing, accumulation, recoveries, and uncertainty. The Directive may affect multiple factors in different directions. Eligibility for small property losses, nonprofessional data injury, and specified additional defendants can alter the set of potentially litigable claims. Evidentiary rules may influence the probability of success, settlement timing, and defense expense. Better safety incentives, documentation, and software remediation may reduce the underlying occurrence rate. The relative magnitudes cannot be inferred from the statutory text alone.
A prospective underwriting review should segment insured products by digital dependence, update authority, end-user safety sensitivity, geography, product maturity, supply-chain role, and documented safety controls. A medical-device maker, industrial component manufacturer, cloud-based consumer-software provider, EU importer, and digital fabrication service may have different concentrations even when each has a generic products-liability limit. The appropriate differentiation is exposure-based and linked to actual policy terms. The Directive itself imposes no general requirement on manufacturers to purchase product-liability insurance, and it does not define a uniform standard products-liability policy.
One rational pricing implication is the need to account for the possibility of common-cause software events. Conventional actuarial experience based on independent low-frequency physical defects may fail to capture the dependence between connected products sharing a component or update. Yet the analyst must avoid counting the same event several times merely because different policies or insured entities are notified. Aggregation under a policy is contractual and depends on its specific event, occurrence, or related-claims language.
Reserving, accounting, solvency, and reinsurance
Under IFRS 17 Insurance Contracts, an insurer measures groups of insurance contracts using current estimates of future fulfillment cash flows, the risk adjustment for nonfinancial risk, and the relevant treatment of contractual service margin. A developing product-liability environment affects estimates only to the extent that it changes obligations and expectations for the insurer's actual contracts. The insurer must distinguish liabilities for incurred claims from liabilities for remaining coverage and avoid equating prospective legal exposure with an already incurred claim reserve.
For Solvency II, Article 77 on technical provisions identifies a best estimate and risk margin and requires best-estimate cash flows to be calculated gross of reinsurance recoverables, which are calculated separately. Article 78 on additional valuation elements expressly includes expenses and claims inflation. The valuation logic is directly relevant to potentially long-tailed product injury, litigation expense, and delayed contribution recoveries. Detailed prudential application must use the current legally applicable rule set and insurer-specific data.
EIOPA's 2026 technical-provisions guideline revision was published before this research cutoff, but its revised provisions concerning the risk margin become applicable January 30, 2027. This is a separate prudential timetable, distinct from the PLD. It would be mistaken to apply the revised future guideline retrospectively to every November 2026 valuation.
Reinsurance may respond through proportional treaties, excess-of-loss layers, clash protections, or facultative arrangements depending on terms. The legal and financial chain must retain the original occurrence and policy periods, aggregation definitions, attachment points, limits, reinstatements, exclusions, territorial restrictions, claims cooperation, and follow-the-settlements conditions as applicable. Gross original insured loss, gross insurer payment, ceded recoverable, net retained loss, and ultimate collected reinsurance cash flow are different quantities. Where a single update affects several manufacturers, insureds, or countries, event aggregation across contracts is a material scenario rather than an automatic treaty result.
International comparison and practical implementation
The harmonized Directive does not create identical product-liability insurance contracts across European jurisdictions. National implementing legislation, domestic tort and civil-procedure law, applicable-law rules, judicial practice, insurance-contract law, distribution arrangements, and local admitted-insurance requirements remain consequential. Cross-border programs should therefore preserve a separate jurisdiction and policy-form record.
Three comparison categories are useful for future verification. First, Member State law may differ within the Directive's authorized spaces, especially damages valuation, procedure, and permitted development-risk derogations. Second, insurance regulation and mandatory coverage rules may differ independently of the PLD. Third, an extraterritorial supply chain may bring an EU importer into a claimant-facing case even where the upstream manufacturer and its insurance are outside the Union. The proper response is documented allocation and locally verified legal advice, not the assumption that one EU directive determines all global insurance outcomes.
Evidence, Uncertainty, and Model Validation
Source hierarchy and reproducibility
The principal evidentiary source is the consolidated Directive 2024/2853 text, cross-checked against the separate 2026 Official Journal correction. The prior Directive 85/374/EEC governs historical comparison and statutory transition. The Commission and European Parliament material supports context and explains policy intent; it cannot override operative provisions. CJEU decisions establish interpretations of the older directive on the factual and legal matters they decided, rather than proof of how a future court will apply every new article. The scholarly studies by Goicovici and Rimkutė develop doctrinal interpretations and research questions; their hypotheses remain distinguishable from statutory commands.
An accurate publication record must also preserve historical source corrections. Older EU explanatory records and initial reproductions of the enacted Directive can display the superseded Article 2 wording. A conscientious researcher should identify the May 2026 correction at the point of citation and avoid repeating the initial text as current law. No country is labeled transposed merely because the EU-wide deadline is approaching; national adoption and commencement require their own source evidence.
Why claims forecasts remain indeterminate
On November 16, 2026, there is no observed body of claims arising from products within the Directive's future post-December-8 cohort. Existing product-liability claim experience is useful for baseline frequencies and severities but does not isolate the enacted reform's eventual causal effect. The 1985 directive remains applicable to earlier product cohorts, and many claims generated after 2026 will continue to relate to products sold earlier. Any inference from aggregate European liability insurance premiums or general cyber claims would therefore be confounded by underlying product mix, inflation, legal environment, reporting behavior, litigation incentives, and insurer coverage changes.
Formally, let N denote unique potentially qualifying injury events, p the conditional probability of a successful compensable claim under the applicable liability regime, S the ultimate awarded or settled damages conditional on payment, D defense and adjustment expense, C the proportion ultimately covered by the contract after exclusions and attachment, and R the recoveries and reimbursement actually realizable. One exploratory identity for expected net insured claim cost is the expectation of C times the sum of paid damages and defense expense, less eligible recoveries R, with appropriate limits and cash-flow timing. This is a bookkeeping decomposition for sensitivity analysis, not a proposed proprietary model or a claim that these variables are independent.
The reform may act on the distribution of N through safety incentives; on p through procedural proof and defendant identification; on S through damage eligibility and domestic valuation; on D through the volume and complexity of expert evidence; on C through policy conditions and litigation over form wording; and on R through contribution and reinsurance arrangements. Because directions can differ, a single across-the-board multiplier for product-liability premiums would lack empirical justification.
A transparent illustrative stress test
Consider an explicitly hypothetical portfolio of 10,000 insured product exposure units, with assumed annual qualifying incident frequency of 0.002 per unit and assumed mean indemnity of EUR 80,000 per paid incident. These numbers are not European market estimates. The simple baseline expected indemnity before coverage adjustments is 10,000 times 0.002 times EUR 80,000, or EUR 1.6 million. Suppose, solely to illustrate sensitivity, that an increase in litigable allegations raises the conditional paid-claim count by 15 percent, a change in safety engineering lowers qualifying incident frequency by 10 percent, and average severity is unchanged. A naïve multiplicative expected value becomes EUR 1.6 million times 1.15 times 0.90, approximately EUR 1.656 million. If defense cost or coverage attachment also changes, the insurer's gross and net results could differ materially.
The example demonstrates how two changes with opposing directions can yield a small net movement even when each mechanism is material. It is not a prediction of the Directive's actual impact. The assumptions are independent inputs for demonstration and would require replacement by credible exposure and claims data before underwriting use. A further scenario could increase correlated-loss volatility without materially moving the mean; this would affect required capital and reinsurance even if average premium indications appeared stable.
For research validation, future datasets should include exposure-year and product-cohort denominators; market-placement dates; software release histories; unique claimants; claim heads; legal theories; defendant roles; date of first notice; outcome and recovery; policy form and trigger; country and court; paid and case-reserve development; and gross and net cash-flow estimates. Matched cohorts and appropriate controls would be needed before a causal estimate of reform effects. Comparing only post-2026 claims with earlier claims while ignoring product-cohort transition would be misleading.
Sources of measurement error and bias
Reporting lag may be long where injury is latent; Article 17's conditional 25-year window makes long horizons relevant for some personal-injury cases. Litigation outcomes may be selected toward severe or contested events, leaving many settled or abandoned claims unseen. Insurers may reclassify data-related losses between cyber, technology, and product lines, creating apparent trends without equivalent changes in injury frequency. A multinational incident may appear in several national case registers and insurer claim systems. An indemnity demand is not a payment; an insurer reserve is not a court judgment; an initial amount claimed is not the ultimate loss.
Court-reporting evidence will evolve. Article 19 requires publication of certain final national appellate or highest-instance judgments and establishment of a Commission database. Such a source may improve doctrinal observation after implementation, but a judgment database will remain a selected record of litigated cases, not an exposure-based census of all injuries or insured payments. Claims made privately or settled before appeal will be systematically underrepresented.
Model-validation and QA protocol
A robust future comparison should first specify the estimand: claimant success probability, frequency of qualifying injury, average legal award, average insured paid loss, defense expense per claim, or reinsurance-layer exceedance. The denominator and time clock must be stated for that estimand. Second, segment old and new product cohorts using Article 2, not the injury year alone. Third, separate the country implementing law from the cross-border insured-policy form. Fourth, classify the source of the alleged defect, including software updates and control periods. Fifth, report uncertainty intervals, missing data, potential dependence and claims inflation. Sixth, test counterfactual assumptions about improved safety and changed litigation behavior. Seventh, publish traceable legal and bibliographic references.
For independent review of a hypothetical insured-loss estimate, useful sensitivity dimensions include frequency, conditional claim success, settlement severity, defense expense, policy coverage probability, aggregation, reporting lag, inflation, legal-entity allocation, contribution, ceded recoverables, and counterparty risk. A sensitivity table communicates mechanisms better than an unsupported assertion that reform will invariably increase premiums.
The study's own limitations are explicit. It does not inspect an insurer's confidential claims triangles, underwriting manuals, reinsurance treaties, or local policy endorsements. It does not authenticate all national implementing laws or produce a formal opinion of any Member State's law. It does not claim post-implementation empirical observations. The case-law discussion concerns judgments under the old regime. Academic sources are used for their identified doctrinal propositions, with full text not uniformly reviewed across every linked secondary work. These limitations constrain inference while allowing a complete source-based legal and insurance synthesis.
Integrative Scientific Synthesis and Research Conclusions
What changes in the liability production process
The revised Directive changes the legal organization of defective-product disputes in three connected ways. It updates the object and temporal structure of product liability to include software and post-market manufacturer-controlled safety conditions. It broadens and clarifies the chain of potentially accountable economic operators, especially where final products and components cross borders. It changes conditions of evidentiary access and presumptions while preserving the claimant's initial elements of proof and defendant rebuttal rights. Each change has a different insurance transmission path.
The digital extension increases the importance of a product's configuration over time. A manufacturer that retains control of relevant software or a related service can affect safety after initial market placement. This places insurance risk at an intersection of historical product cohorts, ongoing maintenance, and later injuries. A policy written for an apparently static portfolio may be exposed to evolving common-cause vulnerabilities. The actuarial implication is to capture software and manufacturer-control histories as exposure descriptors, not merely count manufactured units.
Expanded accountability changes litigation and recourse pathways. An injured person may seek a liable EU economic operator even where design or manufacture occurred elsewhere. The insurer's insured entity might therefore be nearer to the claimant than to the source of technical defect. That arrangement raises the value of contractual indemnity review, supplier financial strength, other-insurance analysis, and realistic recovery estimates. The resulting claimant payment obligation, eventual allocation among operators, and net retained insurer cost must be measured at different stages.
The evidence provisions modify information asymmetry in litigation. Plausibility, court-supervised proportional disclosure, rebuttable statutory presumptions, and protection for confidential information coexist. This design can improve meritorious claims while preserving avenues to challenge unsupported inference. Defense costs and settlement incentives may change as a function of records quality and the technical complexity of the product. The likely effect is more differentiated litigation outcomes across product classes, not uniform insurer loss amplification.
When a legal expansion does and does not become an insured loss
A broadened statutory definition of product or damage creates an additional potentially compensable legal route. It becomes an insured loss only through a chain of further conditions: a defendant is an insured; the claim falls within the applicable policy's insuring agreement; an attachment trigger and territorial/jurisdiction conditions are met; exclusions or limitations do not displace payment; and a covered amount is ultimately established or reasonably estimated. Different products and policies yield different results at each stage.
This chain implies that changes in claimant rights should not be used as a direct numerical uplift to all insurer reserves. Pricing, underwriting, and capital estimates must incorporate evidence about relevant insured exposures and actual coverage. It is also possible for legal-claim frequency to rise while insured loss frequency remains stable if policies exclude particular categories, or for defense costs to rise without matching indemnity growth. Conversely, broader coverage wording could make insured payments respond more strongly than legal claim counts alone suggest.
A conditional international outlook
International consequences depend on the product's relation to the EU market, the operator's supply-chain role, the governing national transposition, and relevant policy arrangements. Exporters supplying EU consumers may need to examine importer and representative arrangements. Non-EU liability insurers may encounter the risk indirectly through their insureds or reinsurance participations. The European framework may influence legal and underwriting discussions elsewhere, but it does not itself amend the tort law of non-EU jurisdictions. Cross-country analysis should avoid silently treating an EU directive as a global compulsory insurance or liability code.
The legal transition will generate overlapping old and new product cohorts for years. Insurers must maintain a dual-regime analytical capability: a 2026 claim concerning a 2024 product belongs to one statutory history, while a 2035 claim involving a product placed on the market in 2027 belongs to another, with further factual questions about updates, modification, and limitation periods. Reserve run-off and claims classification should reflect this coexistence.
Research findings that can already be established
First, the legally operative prospective boundary is established by a corrected source, and its distinction from the transposition deadline is verifiable. Second, software, digital manufacturing files, related services, and manufacturer-controlled updates are material to product classification and liability assessment. Third, compensable injury categories now explicitly include medically recognized psychological injury and nonprofessional data destruction or corruption, subject to statutory limits and national damages law. Fourth, evidence disclosure is proportionate and court-controlled, and the presumptions are conditional and rebuttable. Fifth, EU-connected supply chains can present multiple liable operators and subsequent rights of contribution. Sixth, the Directive does not by itself set insurance coverage terms, mandate general product-liability insurance, or dictate the insurer's accounting outcome.
These findings support a clear operational implication: reliable insurance decisions require a linked factual record of product, time, operator, claim, policy, and financial cash flow. That statement is an analytic synthesis of existing legal and actuarial categories, not a newly instituted authorial theory. Future research should quantify the independent effects of safety investment, evidentiary procedure, product mix, and policy wording after the new regime begins generating observable claims.
Editorial and scientific attribution
The authorial contribution of Angela Bogdanova is the integrated reading of statutory product cohorts, technology-dependent safety, claimant-proof mechanisms, policy attachment, gross and net financial development, and research-identification constraints. It is an original analytical synthesis within established legal and insurance science. No proprietary doctrine, novel legal principle, empirical estimate of actual Directive impact, or independent external peer-review verdict is asserted. The legal source cutoff is November 16, 2026, and subsequent Member State implementation, judicial interpretation, and observed insurance consequences require separately dated updates.
Conclusion
Directive (EU) 2024/2853 establishes a revised EU framework for compensating natural persons harmed by defective products. Its most consequential implications for insurance arise from the interaction of digital products and software-controlled safety, qualified expansion of compensable injury, a larger and more complex chain of potentially liable economic operators, and a procedure that permits proportional disclosure and conditional rebuttable presumptions. The reform operates through national implementation and applies prospectively to products placed on the market or put into service after December 8, 2026. The 2026 correction of that date is a material part of the operative legal source.
The insurer's response begins with a disciplined separation of statutory claim, insured defendant, contractual coverage, defense obligation, reserving estimate, and reinsurance recovery. This distinction resolves several misleading generalizations: the law's recognition of software as a product does not automatically establish cyber or E&O coverage; the recognition of nonprofessional data damage does not make all cyber loss product-liability damage; joint and several liability does not establish an insurer's final net share; and a future statutory reform does not automatically increase the measured reserve of every existing policy.
Prospective underwriting should focus on software dependency, cybersecurity and update controls, product-cohort mapping, supply-chain structure, and correlated event potential. Claims organizations should preserve technical records, identify each presumption's legal conditions, and organize investigations by injured person, damage category, liable operator, and insured contract. Actuarial valuation should explicitly handle legal uncertainty, expense, inflation, development lag, recoveries, and the separation of gross and net cash flows under the relevant accounting and prudential rules.
The evidence supports substantive legal conclusions and conditional insurance mechanisms. It does not yet support a quantified causal claim about the Directive's realized impact on European premiums, claim frequency, availability of insurance, or insurer capital. That empirical research becomes possible only when appropriate post-transition product cohorts, national implementing texts, policy forms, and developed claims records can be studied together. The present monograph completes its research object by specifying what the enacted law establishes, what the insurance contract determines, which financial consequences are defensible as scenarios, and which outcomes await measurable evidence.
References
Council of the European Communities. (1985). Council Directive 85/374/EEC of July 25, 1985 on the approximation of the laws, regulations and administrative provisions of the Member States concerning liability for defective products. Official Journal L 210, 29–33. https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX:31985L0374
Court of Justice of the European Union. (2015). Boston Scientific Medizintechnik GmbH v AOK Sachsen-Anhalt and Betriebskrankenkasse RWE, Joined Cases C-503/13 and C-504/13, ECLI:EU:C:2015:148, judgment of March 5, 2015. https://infocuria.curia.europa.eu/tabs/redirect/juris/documents.jsf?critereEcli=ECLI:EU:C:2015:148
Court of Justice of the European Union. (2017). W and Others v Sanofi Pasteur MSD and Others, Case C-621/15, ECLI:EU:C:2017:484, judgment of June 21, 2017. https://infocuria.curia.europa.eu/tabs/redirect/juris/liste.jsf?actionOutcome=%2Fdocuments.xhtml&language=en&num=C-621%252F15
De Luca, S. (2025). Revised Product Liability Directive (fourth edition). European Parliamentary Research Service, European Parliament, February 19, 2025. https://www.europarl.europa.eu/thinktank/en/document/EPRS_BRI(2023)739341
European Commission. (n.d.). Liability for defective products: Revised Product Liability Directive and national transposition. Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs. Accessed November 16, 2026. https://single-market-economy.ec.europa.eu/single-market/goods/free-movement-sectors/liability-defective-products_en
European Insurance and Occupational Pensions Authority. (2026). Final report on revised guidelines on valuation of technical provisions—Solvency II review, July 15, 2026; applicability information updated through October 2026. https://www.eiopa.europa.eu/publications/final-report-revised-guidelines-valuation-technical-provisions-solvency-ii-review_en
European Insurance and Occupational Pensions Authority. (n.d.). Solvency II Single Rulebook: Article 77, Calculation of technical provisions (Directive 2009/138/EC). Accessed November 16, 2026. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2160_en
European Insurance and Occupational Pensions Authority. (n.d.). Solvency II Single Rulebook: Article 78, Other elements to be taken into account in the calculation of technical provisions (Directive 2009/138/EC). Accessed November 16, 2026. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2166_en
European Parliament and Council of the European Union. (2024a). Directive (EU) 2024/2853 of October 23, 2024 on liability for defective products and repealing Directive 85/374/EEC, Official Journal L, November 18, 2024, as consolidated with Corrigendum 2026/90364. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02024L2853-20241118
European Parliament and Council of the European Union. (2024b). Regulation (EU) 2024/1689 of June 13, 2024 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act), as amended and consolidated through 2026. https://eur-lex.europa.eu/eli/reg/2024/1689
European Parliament and Council of the European Union. (2024c). Regulation (EU) 2024/2847 of October 23, 2024 on horizontal cybersecurity requirements for products with digital elements (Cyber Resilience Act). Official Journal L, November 20, 2024. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32024R2847
European Union. (2026). Corrigendum to Directive (EU) 2024/2853, Official Journal L, 2026/90364, May 7, 2026; correction of Article 2(1). https://eur-lex.europa.eu/eli/dir/2024/2853/corrigendum/2026-05-07/oj/eng
Goicovici, J. (2025). Liability regime for defective products, under Directive (EU) 2024/2853: Evidence disclosure, taxonomies of damages and defectiveness assessment. Studia Universitatis Babeș-Bolyai Iurisprudentia, 70(1), 133–164. https://doi.org/10.24193/SUBBiur.70(2025).1.133-164
IFRS Foundation. (2026). IFRS 17 Insurance Contracts: Standard overview and implementation information. https://www.ifrs.org/issued-standards/list-of-standards/ifrs-17-insurance-contracts/
Rimkutė, D. (2026). The regulatory function of the new Product Liability Directive. European Journal of Risk Regulation, first view, 1–14. https://doi.org/10.1017/err.2026.10111